Abstract 698: Developing a self-targeted cancer immunotherapy using engineered whole tumor cell-based vaccine

The administration of inactivated tumor cell lysate is known to induce a potent antitumor immune response, however, their therapeutic efficacy as shown in Phase I-III clinical trials is limited. This could be attributed to the lack of direct cytotoxic effect on tumor cells and the inability to trigg...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 83; no. 7_Supplement; p. 698
Main Authors Chen, Kok-Siong, Mendonca, Natalia Claire, Borges, Paulo, Shah, Khalid
Format Journal Article
LanguageEnglish
Published 04.04.2023
Online AccessGet full text

Cover

Loading…
Abstract The administration of inactivated tumor cell lysate is known to induce a potent antitumor immune response, however, their therapeutic efficacy as shown in Phase I-III clinical trials is limited. This could be attributed to the lack of direct cytotoxic effect on tumor cells and the inability to trigger a strong antitumor immune response. Unlike inactivated tumor cells, living tumor cells possess a unique potential to home to and self-target tumors. Therefore, repurposing the tumor cells’ self-homing property and natural source of neoantigens is advantageous for self-targeted cancer immunotherapy. In this study, we developed a genetically engineered living whole cancer cell-based therapeutic with direct tumor killing and immunostimulatory roles. We switched the tumor cells from death ligands sensitive to resistant using CRISPR/Cas9 and subsequently engineered them to release dual cell killing and immunomodulatory agents. These engineered therapeutic tumor cells (ThTC) eliminated established tumor and activating antitumor immune cell trafficking and antigen-specific T cell activation signaling. This mechanism-based efficacy of ThTC translated into a marked survival benefit and long-term immunity in primary, recurrent, and metastatic cancer models in immunocompromised, immunocompetent and humanized mice. Arming naturally neoantigen-rich tumor cells with multidisciplinary therapeutics represents promising cell-based immunotherapy for solid tumors and establishes a roadmap towards clinical translation. Citation Format: Kok-Siong Chen, Natalia Claire Mendonca, Paulo Borges, Khalid Shah. Developing a self-targeted cancer immunotherapy using engineered whole tumor cell-based vaccine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 698.
AbstractList The administration of inactivated tumor cell lysate is known to induce a potent antitumor immune response, however, their therapeutic efficacy as shown in Phase I-III clinical trials is limited. This could be attributed to the lack of direct cytotoxic effect on tumor cells and the inability to trigger a strong antitumor immune response. Unlike inactivated tumor cells, living tumor cells possess a unique potential to home to and self-target tumors. Therefore, repurposing the tumor cells’ self-homing property and natural source of neoantigens is advantageous for self-targeted cancer immunotherapy. In this study, we developed a genetically engineered living whole cancer cell-based therapeutic with direct tumor killing and immunostimulatory roles. We switched the tumor cells from death ligands sensitive to resistant using CRISPR/Cas9 and subsequently engineered them to release dual cell killing and immunomodulatory agents. These engineered therapeutic tumor cells (ThTC) eliminated established tumor and activating antitumor immune cell trafficking and antigen-specific T cell activation signaling. This mechanism-based efficacy of ThTC translated into a marked survival benefit and long-term immunity in primary, recurrent, and metastatic cancer models in immunocompromised, immunocompetent and humanized mice. Arming naturally neoantigen-rich tumor cells with multidisciplinary therapeutics represents promising cell-based immunotherapy for solid tumors and establishes a roadmap towards clinical translation. Citation Format: Kok-Siong Chen, Natalia Claire Mendonca, Paulo Borges, Khalid Shah. Developing a self-targeted cancer immunotherapy using engineered whole tumor cell-based vaccine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 698.
Author Shah, Khalid
Borges, Paulo
Chen, Kok-Siong
Mendonca, Natalia Claire
Author_xml – sequence: 1
  givenname: Kok-Siong
  surname: Chen
  fullname: Chen, Kok-Siong
– sequence: 2
  givenname: Natalia Claire
  surname: Mendonca
  fullname: Mendonca, Natalia Claire
– sequence: 3
  givenname: Paulo
  surname: Borges
  fullname: Borges, Paulo
– sequence: 4
  givenname: Khalid
  surname: Shah
  fullname: Shah, Khalid
BookMark eNqdj8tOwzAQRS1UJFrgD7rwD7jYTdwGdhUPsWHH3pqaSZrKj2jsFPXvcQRCrFnN6Opc6dwFm4UYkLGlkiuldHOndNWIbV3r1e5tLdeV2Nw3F2z-G8_-_FdskdJRSqmV1HPmd_uUCWzmpfPAn_CELg596DjwhK4VGajDjB_cQrBIvPd-DDEfkGA48zFNKIauD4hUqM9DdMjz6CNxi86JPaQSn8DagtywyxZcwtufe83ql-f3x1dhKaZE2JqBeg90NkqaaZqZvM3kbb6nmaJZ_bP2Be-PWtQ
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1158/1538-7445.AM2023-698
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage 698
ExternalDocumentID 10_1158_1538_7445_AM2023_698
GroupedDBID ---
-ET
18M
29B
2WC
34G
39C
476
53G
5GY
5RE
5VS
6J9
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CITATION
CS3
DIK
DU5
EBS
EJD
F5P
FRP
GX1
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
PQQKQ
RCR
RHF
RHI
RNS
SJN
TR2
W2D
W8F
WH7
WOQ
YKV
YZZ
ID FETCH-crossref_primary_10_1158_1538_7445_AM2023_6983
ISSN 1538-7445
IngestDate Fri Nov 22 00:55:42 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 7_Supplement
Language English
LinkModel OpenURL
MergedId FETCHMERGED-crossref_primary_10_1158_1538_7445_AM2023_6983
ParticipantIDs crossref_primary_10_1158_1538_7445_AM2023_698
PublicationCentury 2000
PublicationDate 2023-04-04
PublicationDateYYYYMMDD 2023-04-04
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-04
  day: 04
PublicationDecade 2020
PublicationTitle Cancer research (Chicago, Ill.)
PublicationYear 2023
SSID ssj0005105
Score 4.534776
Snippet The administration of inactivated tumor cell lysate is known to induce a potent antitumor immune response, however, their therapeutic efficacy as shown in...
SourceID crossref
SourceType Aggregation Database
StartPage 698
Title Abstract 698: Developing a self-targeted cancer immunotherapy using engineered whole tumor cell-based vaccine
Volume 83
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5qBfEiPvHNHryFxNrmVW-1KsVSQazQW9hstlZsG2lTQX-hP8uZ3W2S1iLWS0iWZLJkPmZnJ9_MEHIWghOAroBZrvq2aXcrzAwvLrjJWVRyGCCACUwUbt27jSf7ruN0CoWvHGtpkoQW_1yYV_IfrcIY6BWzZJfQbCoUBuAc9AtH0DAc_6TjWoiBCp4YbtXHrf11lgHFjLHod01F9AankqN2R8YLpoPopKsPYyIDBUKXJEQiOnbLNZLJIB4ZGNI3cZGLjHfG0__vWVUDlKdrBfXkz2DF6pBWp9-3cjGGuk4Bacav5iN8jedUzQKbiXCm7DwWY2TYpjPHyL3CkP14ymGM04BQj8l4ULMHz0T50EW5Ihkv9py19WxVT9ISC8a0iVa9bjQUvUA2PM2YQcr0uqqbtV7F9dXPBcLBpIf0JVatJSeWPpyvxz23TqbsRblvcvwApQQoJVBSApCyQlaxJCN2cWg-ZHXrHUWmTd-rkzhByvmiueScpJy3094kG3qbQmsKc1ukIIbbZK2liRg7ZDCFHgU5lzQDHmV0BnhUAY_OAI9K4NEMeFQCj0rg0Qx4VANvl9i3N-16w5xON3hTRVKC3z5SZY8Uh_FQ7BPqcI95FS_yuk5kw1rHmF_iflQu8dAteVH3gCwn-nDJ-4_IeobMY1JMRhNxAm5mEp5KDX4D9o98dA
link.rule.ids 314,780,784,27924,27925
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+698%3A+Developing+a+self-targeted+cancer+immunotherapy+using+engineered+whole+tumor+cell-based+vaccine&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Chen%2C+Kok-Siong&rft.au=Mendonca%2C+Natalia+Claire&rft.au=Borges%2C+Paulo&rft.au=Shah%2C+Khalid&rft.date=2023-04-04&rft.issn=1538-7445&rft.eissn=1538-7445&rft.volume=83&rft.issue=7_Supplement&rft.spage=698&rft.epage=698&rft_id=info:doi/10.1158%2F1538-7445.AM2023-698&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2023_698
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon